Integer Holdings Co. (NYSE:ITGR) Given Average Recommendation of “Moderate Buy” by Brokerages

Integer Holdings Co. (NYSE:ITGR) has received a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $146.56.

ITGR has been the topic of several research analyst reports. KeyCorp boosted their price target on shares of Integer from $144.00 to $154.00 and gave the company an “overweight” rating in a report on Friday. Truist Financial boosted their price target on Integer from $147.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Piper Sandler reiterated an “overweight” rating and set a $140.00 price target (up previously from $125.00) on shares of Integer in a report on Friday, October 25th. Benchmark upped their price target on shares of Integer from $130.00 to $140.00 and gave the company a “buy” rating in a report on Monday, October 21st. Finally, Bank of America boosted their price objective on Integer from $135.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, October 1st.

Integer Price Performance

NYSE ITGR opened at $142.79 on Tuesday. The stock’s 50-day moving average price is $137.11 and its two-hundred day moving average price is $129.61. The company has a current ratio of 3.28, a quick ratio of 2.09 and a debt-to-equity ratio of 0.67. Integer has a 1 year low of $94.56 and a 1 year high of $144.22. The company has a market cap of $4.79 billion, a PE ratio of 44.07, a PEG ratio of 1.80 and a beta of 1.12.

Integer (NYSE:ITGR) last issued its earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share for the quarter, beating analysts’ consensus estimates of $1.36 by $0.07. Integer had a return on equity of 11.63% and a net margin of 6.70%. The company had revenue of $431.42 million for the quarter, compared to the consensus estimate of $440.59 million. During the same quarter in the prior year, the company earned $1.27 EPS. The firm’s quarterly revenue was up 8.7% on a year-over-year basis. On average, analysts predict that Integer will post 5.33 EPS for the current year.

Institutional Investors Weigh In On Integer

Several institutional investors and hedge funds have recently bought and sold shares of ITGR. American Century Companies Inc. raised its stake in Integer by 249.7% during the second quarter. American Century Companies Inc. now owns 15,710 shares of the medical equipment provider’s stock worth $1,819,000 after acquiring an additional 11,218 shares in the last quarter. Mercer Global Advisors Inc. ADV boosted its holdings in Integer by 9.0% in the second quarter. Mercer Global Advisors Inc. ADV now owns 30,771 shares of the medical equipment provider’s stock valued at $3,563,000 after acquiring an additional 2,546 shares during the last quarter. Hsbc Holdings PLC increased its position in Integer by 123.3% in the second quarter. Hsbc Holdings PLC now owns 6,458 shares of the medical equipment provider’s stock worth $745,000 after purchasing an additional 3,566 shares during the period. XTX Topco Ltd bought a new stake in Integer during the 2nd quarter worth about $596,000. Finally, Public Sector Pension Investment Board lifted its position in Integer by 7.8% during the 2nd quarter. Public Sector Pension Investment Board now owns 73,672 shares of the medical equipment provider’s stock valued at $8,530,000 after purchasing an additional 5,358 shares during the period. Institutional investors own 99.29% of the company’s stock.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.